Genetic basis of hypertrophic cardiomyopathy

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 6, 2006, Pages 927-934

  Lind, Joanne M ^a,b,c   Chiu, Christine ^c   Semsarian, Christopher ^a,b,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Faculty of Medicine   (Australia)

^c CENTENARY INSTITUTE   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cardiomyopathy; Genes; Genetic screening; Hypertrophic; Mutations; Sarcomere

Indexed keywords

ADENOSINE PHOSPHATE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALSEQUESTRIN; CAVEOLIN 3; CONNECTIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; LIM PROTEIN; LOSARTAN; MYOSIN BINDING PROTEIN C; PHOSPHOLAMBAN; PROTEIN KINASE; RYANODINE RECEPTOR; SPIRONOLACTONE; TROPONIN C; TROPONIN I; TROPONIN T;

DEFIBRILLATOR; ELECTROCARDIOGRAM; ENZYME POLYMORPHISM; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC SCREENING; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FUNCTION; HEART LEFT VENTRICLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LIFESTYLE MODIFICATION; LINKAGE ANALYSIS; M MODE ECHOCARDIOGRAPHY; MUSCLE RESECTION; MUTATION RATE; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; SARCOMERE; SIGNAL TRANSDUCTION; SYNCOPE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

CARDIOMYOPATHY, HYPERTROPHIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MUTATION; SARCOMERES;

EID: 33845913222     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.6.927     Document Type: Review

References (70)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br. Heart J. 20(1), 1-8 (1958).
2. Maron BJ, Gardin JM, Flack JM et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92(4), 785-789 (1995).
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N. Engl. J Med. 336(11), 775-785 (1997).
4. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J. Am. Coll. Cardiol. 41(6), 987-993 (2003).
5. Wolf CM, Moskowitz IP, Arno S et al. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc. Natl Acad. Sci. USA 102(50), 18123-18128 (2005).
6. Jayatilleke I, Dootan A, Ingles J et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am. J. Cardiol. 93(9), 1192-1194 (2004).
7. Roberts R, Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation 112(2), 293-296 (2005).
8. Jarcho JA, McKenna W, Pare JA et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N. Engl. J. Med. 321(20), 1372-1378 (1989).
9. Geisterfer-Lowrance AA, Kass S, Tanigawa G et al. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense mutation. Cell 62(5), 999-1006 (1990).
10. Solomon SD, Jarcho JA, McKenna W et al. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J. Clin. Invest. 86(3), 993-999 (1990).
11. Watkins H, MacRae C, Thierfelder L et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat. Genet. 3(4), 333-337 (1993).
12. Thierfelder L, MacRae C, Watkins H et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc. Natl Acad. Sci. USA 90(13), 6270-6274 (1993).
13. Watkins H, Conner D, Thierfelder L et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 11(4), 434-437 (1995).
14. Poetter K, Jiang H, Hassanzadeh S et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat. Genet. 13(1), 63-69 (1996).
15. Kimura A, Harada H, Park JE et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 16(4), 379-382 (1997).
16. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 17(6), 524 (2001).
17. Hayashi T, Arimura T, Itoh-Satoh M et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 44(11), 2192-2201 (2004).
18. Geier C, Perrot A, Ozcelik C et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107(10), 1390-1395 (2003).
19. Satoh M, Takahashi M, Sakamoto T et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem. Blophys. Res. Commun. 262(2), 411-417 (1999).
20. Anan R, Greve G, Thierfelder L et al. Prognostic implications of novel β cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J. Clin. Invest. 93(1), 280-285 (1994).
21. Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J. 14(9), 1952-1960 (1995).
22. Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiac myocytes. Prog. Cardiovasc. Dis. 47(3), 159-176 (2004).
23. Moolman JC, Corfield VA, Posen B et al. Sudden death due to troponin T mutations. J. Am. Coll. Cardiol. 29(3), 549-555 (1997).
24. Doolan A, Tebo M, Ingles J et al. Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. J. Mol. Cell. Cardiol. 38(2), 387-393 (2005).
25. Kokado H, Shimizu M, Yoshio H et al. Clinical features of hypertrophic: cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation 102(6), 663-669 (2000).
26. Crilley JG, Boehm EA, Blair E et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol. 41(10), 1776-1782 (2003).
27. Somura F, Izawa H, Iwase M et al. Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation 104(6), 658-663 (2001).
28. Hasegawa K, Fujiwara H, Koshiji M et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 27(2), 259-264 (1996).
29. Li RK, Li G, Mickle DA et al. Overexpression of transforming growth factor-β1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96(3), 874-881 (1997).
30. Hayashi T, Arimura T, Ueda K et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 313(1), 178-184 (2004).
31. Haghighi K, Kolokathis F, Gramolini AO et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl Acad. Sci. USA 103(5), 1388-1393 (2006).
32. Haghighi K, Kolokathis F, Pater L et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111(6), 869-876 (2003).
33. Schmitt JP, Kamisago M, Asahi M et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299(5611), 1410-1413 (2003).
34. Minamisawa S, Sato Y, Tatsuguchi Y et al. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 304(1), 1-4 (2003).
35. Gollob MH, Green MS, Tang AS et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med. 344(24), 1823-1831 (2001).
36. Arad M, Maron BJ, Gorham JM et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N. Engl. J. Med. 352(4), 362-372 (2005).
37. Blair E, Redwood C. Ashrafian H et al. Mutations in the γ(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10(11), 1215-1220 (2001).
38. Chimenti C, Pieroni M, Morgante E et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110(9), 1047-1053 (2004).
39. Yang Z, McMahon CJ, Smith LR et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 112(11), 1612-1617 (2005).
40. Murphy RT, Thaman R, Blanes JG et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur. Heart J. 26(2), 187-192 (2005).
41. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 82 (2), 507-513 (1990).
42. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin. Proc. 80(6), 739-744 (2005).
43. Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107(17), 2227-2232 (2003).
44. Van Driest SL, Vasile VC, Ommen SR et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44(9), 1903-1910 (2004).
45. Ingles J, Doolan A, Chiu C et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J. Med. Genet. 42(10), E59 (2005).
46. Semsarian C, Ahmad I, Giewat M et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109(8), 1013-1020 (2002).
47. Tiso N, Stephan DA, Nava A et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricutar cardiomyopathy type 2 (ARVD2). Hum. Mol. Genet. 10(3), 189-194 (2001).
48. Priori SG, Napolitano C, Tiso N et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103(2), 196-200 (2001).
49. Lahat H, Pras E, Olender T et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am. J. Hum. Genet. 69(6), 1378-1384 (2001).
50. Semsarian C, Healey MJ, Fatkin D et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 33(11), 2055-2060 (2001).
51. Doolan G, Nguyen L, Chung J, Ingles J, Semsarian C. Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy. Int. J. Cardiol. 96(2), 157-163 (2004).
52. Osterop AP, Kofflard MJ, Sandkuijl LA et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 32(5), 825-830 (1998).
53. Deinum J, van Gool JM, Kofflard MJ, ten Cate FJ, Danser AH, Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 38(6), 1278-1281 (2001).
54. Patel R, Lim DS, Reddy D et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 32(12), 2369-2377 (2000).
55. Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 342(6). 365-373 (2000).
56. Lim DS, Lutucuta S, Bachireddy P et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103(6), 789-791 (2001).
57. Senthil V, Chen SN, Tsybouleva N et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ. Res. 97(3), 285-292 (2005).
58. Tsybouleva N, Zhang L, Chen S et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 109(10), 1284-1291 (2004).
59. Van Driest SL, Ackerman MJ, Ommen SR et al. Prevalence and severity of 'benign' mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 106(24), 3085-3090 (2002).
60. Van Driest SL, Ellsworth EG, Ommen SR et al. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation 108(4), 445-451 (2003).
61. Van Driest SL, Jaeger MA, Ommen SR et al. Comprehensive analyst of the β-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44(3), 602-610 (2004).
62. Ackerman MJ, VanDriest SL, Ommen SR et al. Prevalence and age-dependence of malignant mutations in the P-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J. Am. Coll. Cardiol. 39(12), 2042-2048 (2002).
63. Erdmann J, Daehmlow S, Wischke S et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin. Genet. 64(4), 339-349 (2003).
64. Morner S, Richard P, Kazzam E et al. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. J. Mol. Cell. Cardiol. 35(7), 841-849 (2003).
65. Jaaskelainen P, Soranta M, Miettinen R et al. The cardiac β-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J. Am. Coll. Cardiol. 32(6), 1709-1716 (1998).
66. Jaaskelainen P, Miettinen R, Silvennoinen K et al. The cardiac troponin I gene is not associated with hypertrophic cardiomyopathy in patients from eastern Finland. J. Mol. Cell. Cardiol. 31(11), 2031-2036 (1999).
67. Jaaskelainen P, Kuusisto J, Miettinen R et al. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland. J. Mol. Med. 80(7), 412-422 (2002).
68. Karkkainen S, Peuhkurinen K, Jaaskelainen P et al. No variants in the cardiac actin gene in Finnish patients with dilated or hypertrophic cardiomyopathy. Am. Heart J. 143(6), E6 (2002).
69. Garcia-Castro M, Reguero JR, Batalla A et al. Hypertrophic cardiomyopathy: low frequency of mutations in the β-myosin heavy chain (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients. Clin. Chem. 49(8), 1279-1285 (2003).
70. Seidman JG, Seidman CE. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104(4), 557-567 (2001).